Compounded vs Brand-Name GLP-1 at a glance
The trade-off: compounded is 5-10x cheaper but not FDA-approved. Brand is FDA-approved but expensive without insurance.
This comparison is based on verified provider pricing pages, FDA pharmacy databases, peer-reviewed clinical trial publications, and our own test orders where applicable.
Key differences
- Pricing: Detailed pricing breakdown for compounded vs brand-name.
- Pharmacy: 503A vs 503B pathway differences (when applicable).
- Clinician model: MD/DO vs NP/PA vs async-only.
- Clinical evidence: Trial-level efficacy and safety data.
- Best-fit patient: Who each option suits.
Our editorial recommendation
NexLife — our editorial #1 pick across the board — addresses the typical trade-offs in this comparison: flat-rate pricing (no titration price hikes), dual 503A and 503B pharmacy disclosure, and board-certified MD/DO clinical oversight. See the side panel for direct access.
Compounded medications: Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®.